BridgeBio Pharma Inc
For the period ended Sep 30, 2024. Filed Nov 12, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 12, 2024
BBIO$77.93+4.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
| Three Months Ended September 30, | Nine Months Ended September 30, | |||
|---|---|---|---|---|
| 2024 | 2023 | 2024 | 2023 | |
| Revenue | $2,732 | $4,091 | $216,020 | $7,558 |
| Operating costs and expenses: | ||||
| Cost of revenue | 598 | 598 | 1,794 | 1,848 |
| Research and development | 120,444 | 125,136 | 376,111 | 325,485 |
| Selling, general and administrative | 68,819 | 35,777 | 194,149 | 103,007 |
| Restructuring, impairment and related charges | 4,621 | 272 | 10,912 | 7,172 |
| Total operating costs and expenses | 194,482 | 161,783 | 582,966 | 437,512 |
| Loss from operations | (191,750) | (157,692) | (366,946) | (429,954) |
| Other income (expense), net: | ||||
| Interest income | 3,296 | 3,793 | 12,566 | 12,460 |
| Interest expense | (23,061) | (20,306) | (69,469) | (61,021) |
| Gain on deconsolidation of subsidiaries | 52,027 | — | 178,321 | — |
| Loss on extinguishment of debt | — | — | (26,590) | — |
| Net loss from equity method investments | (6,563) | — | (14,488) | — |
| Other income (expense), net | 1,797 | (5,283) | 10,648 | (4,408) |
| Total other income (expense), net | 27,496 | (21,796) | 90,988 | (52,969) |
| Net loss | (164,254) | (179,488) | (275,958) | (482,923) |
| Net loss attributable to redeemable convertible noncontrolling interests and noncontrolling interests | 2,214 | 2,489 | 5,246 | 7,869 |
| Net loss attributable to common stockholders of BridgeBio | $(162,040) | $(176,999) | $(270,712) | $(475,054) |
| Net loss per share attributable to common stockholders of BridgeBio, basic and diluted | $(0.86) | $(1.08) | $(1.46) | $(2.99) |
| Weighted-average shares used in computing net loss per share attributable to common stockholders of BridgeBio, basic and diluted | 188,510,372 | 163,308,632 | 184,947,173 | 158,891,152 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.